

Estimate change	
TP change	
Rating change	

Bloomberg	TRP IN
Equity Shares (m)	338
M.Cap.(INRb)/(USDb)	1380.1 / 15.2
52-Week Range (INR)	4240 / 2886
1, 6, 12 Rel. Per (%)	5/9/22
12M Avg Val (INR M)	1181

Financials & Valuations (INRb)

Y/E March	FY26E	FY27E	FY28E
Sales	139.9	190.0	219.1
EBITDA	45.5	65.2	76.5
Adjusted PAT	22.7	25.5	37.0
EBIT Margin (%)	24.6	22.2	24.5
Cons. Adj EPS (INR)	59.6	67.0	97.3
EPS Gr. (%)	16.0	12.4	45.2
BV/Sh. (INR)	1,421.8	1,518.1	1,657.8
Ratios			
Net D-E	0.5	0.3	0.2
ROE (%)	14.3	10.2	13.8
RoCE (%)	11.1	9.4	12.2
Payout (%)	36.6	36.1	36.1
Valuation			
P/E (x)	63.7	56.7	39.0
EV/EBITDA (x)	30.1	20.6	17.0
Div. Yield (%)	0.5	0.5	0.8
FCF Yield (%)	-15.5	3.4	4.7
EV/Sales (x)	9.8	7.1	5.9

Shareholding Pattern (%)

As On	Dec-25	Sep-25	Dec-24
Promoter	68.3	68.3	68.3
DII	9.2	9.3	8.4
FII	16.1	15.9	16.2
Others	6.4	6.5	7.2

FII includes depository receipts

CMP: INR4,078 **TP: INR4,300 (+5%)** **Neutral**

DF/LATAM outperforms; Germany underperforms

Efforts underway to integrate JB Pharma

- Torrent Pharma (TRP) delivered a better-than-expected performance, with 3%/5%/10% beat on revenue/EBITDA/PAT in 3QFY26. Growth was aided by consistent superior execution in domestic formulation (DF)/LATAM, favorable currency benefits in the US, and a lower tax rate.
- In DF, TRP continued to outpace the industry with strong volume offtake, price hike and new launches. Even the OTC sub-segment has been scaling up on the back of promotions and increasing reach through increased number of MRs.
- While industry YoY growth has been moderate in Brazil, TRP has exceeded industry YoY growth, largely led by new launches. It is well positioned for new introductions in this market.
- With gaining control of JB Pharma (JBCP) acquisition effective 21st Jan'26, TRP is geared up to build synergy from the integration through cost efficiency and collective revenue growth.
- After consolidating different aspects of JBCP with TRP in 3-6 months, we expect meaningful benefits to accrue from 4QFY27 onward.
- We have consolidated the financials of JBCP with TRP from 4QFY26. We have lowered our EPS estimates by 15%/21%/7% for FY26/FY27/FY28, as a) the addition of EBITDA from JBCP would be more than offset by interest cost/amortization in the initial years; and b) we consider dilution due to JBCP acquisition. The merger is expected to raise the equity shares of TRP by ~42m. We expect 28% earnings CAGR over FY26-28 on the back of a) sustained outperformance in TRP's existing business, b) addition of JBCP business, and c) integration benefits.
- We value TRP 24x 12M forward EB/EBITDA and reduce net debt to INR133b to arrive at a TP of INR4,300. Given limited upside from the current levels, we maintain Neutral rating on the stock.

Consistent profitable growth for 13 quarters

- Sales grew 17.6% YoY to INR33b.
- Gross margin contracted 20bp at 75.8%.
- EBITDA margin expanded by 40bp YoY to 32.9%.
- Accordingly, EBITDA grew 19% YoY to INR10.9b (vs our Est: INR10.3b).
- Adj. PAT grew 27.8% YoY to INR6.4b.
- For 9MFY26, revenue/EBITDA/PAT grew 14%/16%/26% YoY.

DF/LATAM on a robust YoY growth path

- Sales grew 17.6% YoY to INR33b.
- India formulations revenue grew 13.7% YoY to INR18b (54.5% of sales).
- US generics grew 18.5% YoY to INR3.2b (10% of sales).
- Germany sales grew by 7.8% YoY to INR3b (9% of sales).
- LATAM business grew by 27.5% YoY to INR3.7b (11% of sales).
- ROW+CDMO sales grew 32.6% YoY at INR5.1b (15.5% of sales).

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst – Eshita Jain (Eshita.Jain@MotilalOswal.com) | **Vipul Mehta** (vipul.mehta@motilaloswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights from the management commentary

- TRP indicated synergy benefits of INR4b-INR4.5b from integrating JBCP over the next 2-3 years, largely driven by the cost efficiency.
- Despite announcement of JBCP acquisition, attrition in JBCP's marketing team has been in the historical range.
- With JBCP EBITDA margin at 28-29% and TRP EBITDA margin at 32-33%, there is a scope to bring JBCP margins to TRP margin level in FY27.
- Germany business is impacted by continued disruption from a third-party supplier, which has got a regulatory issue and it is difficult to predict the timeline to resolve it. TRP is working on the alternate supplier, which would take 3-4 quarters.

Quarterly performance (Consolidated)

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	Var. 3QE vs Est
	INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			
Net Revenues	28,590	28,890	28,090	29,590	31,780	33,020	33,030	42,055	1,15,160	1,39,885	31,944	3.4
YoY Change (%)	10.3	8.6	2.8	7.8	11.2	14.3	17.6	42.1	7.3	21.5	13.7	
EBITDA	9,240	9,390	9,140	9,810	10,470	10,830	10,880	13,289	37,580	45,469	10,318	5.4
YoY Change (%)	16.8	13.8	5.2	11.1	13.3	15.3	19.0	35.5	11.6	21.0	12.9	
Margins (%)	32.3	32.5	32.5	33.2	32.9	32.8	32.9	31.6	32.6	32.5	32.3	
Depreciation	1,970	1,980	1,990	2,010	2,010	2,040	2,060	5,012	7,950	11,122	2,086	
EBIT	7,270	7,410	7,150	7,800	8,460	8,790	8,820	8,277	29,630	34,347	8,232	7.1
Margins (%)	25.4	25.6	25.5	26.4	26.6	26.6	26.7	19.7	25.7	24.6	25.8	
Interest	750	640	570	560	560	480	450	2,410	2,520	3,900	520	
Other Income	240	-160	330	-180	-370	-270	-130	171	230	-599	182	
PBT before EO Expense	6,760	6,610	6,910	7,060	7,530	8,040	8,240	6,038	27,340	29,848	7,894	4.4
One-off expenses	200	0	0	410	150	130	100	0	610	380	0	
PBT after EO Expense	6,560	6,610	6,910	6,650	7,380	7,910	8,140	6,038	26,730	29,468	7,894	
Tax	1,990	2,080	1,880	1,670	1,900	2,000	1,790	1,389	7,620	7,079	2,029	
Rate (%)	29.4	31.5	27.2	23.7	25.2	24.9	21.7	23.0	27.9	23.7	25.7	
Reported PAT	4,570	4,530	5,030	4,980	5,480	5,910	6,350	4,649	19,110	22,389	5,865	8.3
Adj PAT	4,709	4,530	5,030	5,287	5,591	6,007	6,428	4,649	19,556	22,676	5,865	9.6
YoY Change (%)	24.6	17.4	31.9	17.8	18.7	32.6	27.8	-12.1	22.7	16.0	16.6	
Margins (%)	16.5	15.7	17.9	17.9	17.6	18.2	19.5	11.1	17.0	16.2	18.4	

E: MOSL Estimates

KPIs (Consolidated)

Y/E March	FY25				FY26E				FY25	FY26E	FY26E	Var. 3QE vs Est	
	INRm	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE				
India formulations	16,350	16,320	15,810	15,450	18,110	18,200	17,980	17,319	63,930	71,609	17,391	3.4	
YoY Change (%)	14.7	13.0	11.7	12.0	10.8	11.5	13.7	12.1	12.8	12.0	10.0		
US generics	2,590	2,680	2,710	3,020	3,080	3,370	3,210	3,870	11,000	13,530	3,320	-3.3	
YoY Change (%)	-11.6	8.1	-1.1	15.3	18.9	25.7	18.5	28.1	2.0	23.0	22.5		
Latin America	1,960	2,630	2,910	3,510	2,180	3,180	3,710	3,686	11,000	12,756	3,434	8.0	
YoY Change (%)	3.2	4.4	-6.7	-5.6	11.2	20.9	27.5	5.0	-2.3	16.0	18.0		
Europe	2,840	2,880	2,820	2,860	3,080	3,030	3,040	3,003	11,390	12,153	2,961	2.7	
YoY Change (%)	10.1	8.3	4.4	2.1	8.5	5.2	7.8	5.0	6.1	6.7	5.0		
Others (ROW+CDMO)	4,850	4,380	3,840	4,750	5,330	5,240	5,090	5,083	17,840	20,743	4,838.4	5.2	
YoY Change (%)	14.4	-2.7	-16.7	5.3	9.9	19.6	32.6	7.0	0.0	16.3	26.0		
Cost Break-up													
RM Cost (% of Sales)	24.3	23.5	24.0	24.1	24.4	24.2	24.2	24.4	24.4	24.3	24.2		
Staff Cost (% of Sales)	19.2	18.8	19.5	19.0	19.0	19.7	19.5	19.5	19.5	19.3	19.3		
Other Cost (% of Sales)	24.2	25.2	24.0	23.8	23.7	24.0	23.2	24.5	24.7	23.9	24.2		
Gross Margins(%)	75.7	76.5	76.0	75.9	75.6	75.8	75.8	75.6	75.6	75.7	75.8		
EBITDA Margins(%)	32.3	32.5	32.5	33.2	32.9	32.8	32.9	31.6	32.6	32.5	32.3		
EBIT Margins(%)	25.4	25.6	25.5	26.4	26.6	26.6	26.7	19.7	25.7	24.6	25.8		

Exhibit 1: Top 10 drugs

Drug	Therapy	MAT Dec'25			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Dec'25
Total		85,413	8.8	100.0	11.5	15.5
Shelcal	Vitamins/Minerals/Nutrients	3,471	0.2	33.7	13.1	16.2
Chymoral	Pain / Analgesics	3,392	4.9	88.7	17.1	22.7
Nexpro-Rd	Gastro Intestinal	2,661	14.5	25.2	10.9	15.9
Nikoran	Cardiac	2,474	16.9	53.2	21.5	27.5
Shelcal Xt	Vitamins/Minerals/Nutrients	2,367	1.9	19.6	5.9	10.1
Unienzyme	Gastro Intestinal	1,671	0.6	40.8	6.9	11.3
Nebicard	Cardiac	1,485	5.2	52.8	8.1	12.1
Nexpro	Gastro Intestinal	1,454	21.3	30.0	19.2	22.0
Losar	Cardiac	1,395	1.1	61.8	1.8	6.6
Veloz-D	Gastro Intestinal	1,322	5.4	10.3	5.5	10.2


Three-months: Oct-Dec'25

Source: IQVIA, MOFSL


Exhibit 2: Therapy mix (%)

	Share	MAT growth (%)	3M*	Dec'25
Total	100.0	8.8	11.5	15.5
Cardiac	27.7	10.8	12.2	16.7
Gastro Intestinal	17.9	10.0	11.7	15.4
Neuro / Cns	15.0	11.0	12.3	16.5
Vitamins/Minerals/Nutrients	9.6	5.1	14.7	18.8
Anti Diabetic	9.3	11.7	9.9	13.0
Pain / Analgesics	7.9	5.8	14.5	19.1

Source: IQVIA, MOFSL

Exhibit 3: Acute vs. Chronic (MAT growth)


Source: IQVIA, MOFSL

Exhibit 4: Growth distribution (%) (MAT Dec'25)


Source: IQVIA, MOFSL




Key takeaways from the management interaction

- TRP expects that substitution of semaglutide in Brazil for weight loss would be minimal given strict regulatory constraints.
- Volume/price/new launches grew 5.5%/5.8%/2.2% YoY in DF compared to 1.2%/6.6%/2.8% YoY for IPM in 3QFY26.
- Current MR strength is 6,900, which TRP plans to take to 7,000 by FY26 end.
- Curatio portfolio grew 27% YoY in 3Q, driven by demand generation due to OTC ad spends and addition of MRs.
- In Brazil, TRP plans to launch 5-6 products per year and revenue growth of 10-15% YoY on an annual basis.
- TRP witnessed 12% CC YoY growth in the US, driven by new launches and increased purchases from existing contracts.


Key exhibits

Exhibit 5: US sales rose 12.5% YoY in 3QFY26 (CC terms)




Source: MOFSL, Company

Exhibit 6: India sales grew ~13.7% YoY in 3QFY26




Source: MOFSL, Company

Exhibit 7: Germany sales grew 7.8% YoY in 3QFY26




Source: Company, MOFSL

Exhibit 8: Brazil's revenue grew 27.5% YoY in 3QFY26




Source: Company, MOFSL

Exhibit 9: EBITDA margin expanded marginally 40bp YoY



Source: MOFSL, Company

Exhibit 10: Adjusted PAT rose 27.8% YoY in 3QFY26



Source: MOFSL, Company

JB integration - one more growth catalyst

DF – Consistent chronic outperformance and portfolio deepening

- In 9MFY26, TRP's India business grew 12% YoY to INR54.3b.
- 3Q growth of 14% YoY was led by 5.5% volume growth vs. market volume growth of 1.2%, supported by strong traction in chronic and sub-chronic therapies, including cardiac, gastro and diabetes.
- Price growth (5.8%) was broadly in line with market (5.6%), while new product contribution (2.7%) remained steady, reflecting balanced growth drivers.
- Curatio business continued strong momentum with 27% growth in 3Q and 9M, aided by OTC advertising push and field force expansion.
- Field force strength increased to 6,900 and is expected to cross 7,000 by FY26-end, with further expansion visibility toward ~7,500 by FY27, supporting penetration and productivity gains.
- Management expects continued above-market growth, driven by market share gains in focus therapies, improved field force productivity and scaling of Curatio portfolio.
- JBCP acquisition strengthens domestic portfolio depth in cardiac and gastro, with potential revenue synergies over time through enhanced reach and cross-leveraging of divisions.
- We expect a 14% sales CAGR in DF to INR95.9b over FY25-28, driven by chronic therapy leadership, Curatio scale-up, field force expansion, cross-selling opportunities from JB portfolio and sustained market share gains.

Brazil – Branded growth momentum with GLP-1 upside

- In 9MFY26, the Brazilian business grew 21% YoY to INR9.1b.
- Brazil 3Q revenue stood at BRL224m in CC terms, growing 10% YoY vs. market growth of ~7%, reflecting continued outperformance.
- Secondary sales grew 13%, supported by healthy volume growth and mid-single digit price increases despite a moderating macro inflation environment.
- TRP has a strong pipeline of 60 molecules awaiting ANVISA approval, providing multi-year launch visibility.
- Management expects base business (ex-Semaglutide) to grow in the 10-15% range, driven by new launches (5-6 annually), selective price increases and prescription momentum.

- Brazil GLP-1 opportunity (Semaglutide) represents a significant growth lever, with Ozempic (~USD270m market) filed and Wegovy to follow; approval timing depends on ANVISA but product is being prioritized.
- Accordingly, we expect a 14% sales CAGR over FY25-28, reaching INR16.4b, supported by steady branded portfolio expansion, disciplined pricing, strong approval pipeline and medium-term upside from GLP-1 launches.


US – Pipeline-led scaling from sub-scale base

- TRP continued its momentum with 21% YoY growth in US generics sales to INR9.7b in 9MFY26. In cc terms, it exhibited 19% YoY growth.
- Business remains relatively small (USD150–160m annual run rate), with performance largely dependent on timing and competitiveness of new launches.
- Growth in recent quarters has come from successful new launches achieving target market share and improved execution on contract volumes.
- Pipeline augmentation is underway to support scale expansion, though revenue visibility remains sensitive to launch timing and competitor entry.
- We expect an 18% sales CAGR over FY25-28, reaching INR18.1b, driven by disciplined launch execution, pipeline augmentation, selective contract wins and gradual scaling toward a more meaningful revenue base.

Maintain Neutral


- We have consolidated the financials of JBCP with TRP from 4QFY26. We have lowered our EPS estimates by 15%/21%/7% for FY26/FY27/FY28, as a) the addition of EBITDA from JB pharma would be more than offset by interest cost/amortization in the initial years, and b) we consider dilution due to JBCP acquisition. The merger is expected to raise the equity shares of TRP by ~42m. We expect 28% earnings CAGR over FY26-28 on the back of a) sustained outperformance in TRP's existing business, b) addition of JBCP business, and c) integration benefits.
- We value TRP 24x 12M forward EB/EBITDA and reduce the net debt to INR133b to arrive at a TP of INR4,300. Given limited upside from the current levels, we maintain Neutral rating on the stock.

Exhibit 11: P/E chart




Source: MOFSL, Company, Bloomberg

Exhibit 12: EV/EBITDA chart




Story in charts

Exhibit 13: Expect total sales CAGR of 24% over FY25-28




Source: Company, MOFSL

Exhibit 14: EBITDA margin to expand 230bp over FY25-28




Source: Company, MOFSL

Exhibit 15: Expect 14.5% DF sales CAGR over FY25-28




Source: Company, MOFSL

Exhibit 16: Expect 19% US sales (USDm) CAGR over FY25-28




Source: Company, MOFSL

Exhibit 17: Expect ~14.2% sales CAGR in Brazil over FY25-28



Source: Company, MOFSL

Exhibit 18: Expect 13.6% sales CAGR in Germany over FY25-28



Source: Company, MOFSL

Financials and valuations

Income Statement							(INR m)
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Net Sales	85,080	95,820	1,07,280	1,15,160	1,39,885	1,90,006	2,19,099
Change (%)	6.3	12.6	12.0	7.3	21.5	35.8	15.3
EBITDA	24,310	28,288	33,680	37,580	45,469	65,172	76,466
Margin (%)	28.6	29.5	31.4	32.6	32.5	34.3	34.9
Depreciation	6,620	7,070	8,080	7,950	11,122	22,943	22,753
EBIT	17,690	21,218	25,600	29,630	34,347	42,229	53,712
Int. and Finance Charges	2,550	3,330	3,540	2,520	3,900	9,060	5,521
Other Income - Rec.	1,970	850	580	230	-599	1,050	1,150
PBT before EO Expense	17,110	18,738	22,640	27,340	29,848	34,219	49,342
EO Expense/(Income)	4,850	267	-880	610	380	0	0
PBT after EO Expense	12,260	18,471	23,520	26,730	29,468	34,219	49,342
Current Tax	4,490	6,110	6,959	7,618	7,077	8,724	12,333
Deferred Tax	0	0	1	2	2	2	2
Tax	4,490	6,110	6,960	7,620	7,079	8,726	12,335
Tax Rate (%)	26.2	32.6	30.7	27.9	23.7	25.5	25.0
Reported PAT	7,770	12,361	16,560	19,110	22,389	25,493	37,006
Less: Minority Interest	0	0	0	0	0	0	0
Net Profit	7,770	12,361	16,560	19,110	22,389	25,493	37,006
Adj PAT	11,617	12,581	15,942	19,556	22,676	25,493	37,006

Balance Sheet

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	850	1,692	1,692	1,692	1,902	1,902	1,902
Other Reserves	58,680	60,288	66,868	74,218	2,38,703	2,54,988	2,78,629
Total Reserves	58,680	60,288	66,868	74,218	2,38,703	2,54,988	2,78,629
Net Worth	59,530	61,980	68,560	75,910	2,40,605	2,56,890	2,80,531
Deferred liabilities	-4940	-5440	-5548	2340	2340	2340	2340
Total Loans	40,180	52,970	39,380	30,260	1,15,380	73,380	66,380
Capital Employed	94,770	1,09,510	1,02,392	1,08,510	3,58,325	3,32,610	3,49,251
Gross Block	1,04,548	1,27,128	1,38,405	1,43,978	3,77,478	3,80,481	3,83,981
Less: Accum. Deprn.	37,298	44,368	52,448	60,398	77,069	1,00,012	1,22,765
Net Fixed Assets	67,250	82,760	85,957	83,580	3,00,408	2,80,469	2,61,216
Capital WIP	6,720	8,330	2,810	3,670	3,670	3,670	3,670
Investments	440	450	350	470	470	470	470
Curr. Assets	51,650	53,140	56,110	56,230	94,981	1,01,177	1,47,532
Inventory	24,620	22,300	22,790	25,410	30,830	41,705	47,693
Account Receivables	16,330	19,440	18,440	18,670	23,780	34,201	39,438
Cash and Bank Balance	4,030	5,710	8,390	5,790	33,336	17,492	51,796
Loans & Advances	6,670	5,690	6,490	6,360	7,034	7,779	8,604
Curr. Liability & Prov.	31,290	35,170	42,837	35,440	41,203	53,176	63,636
Account Payables	23,490	27,300	34,387	26,350	32,307	43,098	49,040
Provisions	7,800	7,870	8,450	9,090	8,896	10,078	14,596
Net Current Assets	20,360	17,970	13,273	20,790	53,778	48,001	83,896
Appl. of Funds	94,770	1,09,510	1,02,390	1,08,510	3,58,325	3,32,610	3,49,251

E: MOSL Estimates

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
EPS	30.5	33.1	41.9	51.4	59.6	67.0	97.3
Cash EPS	42.5	57.4	72.8	159.9	198.0	286.2	353.1
BV/Share	175.9	183.1	202.6	448.6	1,421.8	1,518.1	1,657.8
DPS	10.3	11.2	14.1	17.3	17.9	20.1	29.2
Payout (%)	54.0	36.8	34.8	37.0	36.6	36.1	36.1
Valuation (x)							
P/E	124.4	114.9	90.6	73.9	63.7	56.7	39.0
Cash P/E	89.3	66.2	52.2	23.8	19.2	13.3	10.8
P/BV	21.6	20.7	18.7	8.5	2.7	2.5	2.3
EV/Sales	15.5	13.9	12.3	11.4	9.8	7.1	5.9
EV/EBITDA	54.4	47.1	39.1	34.9	30.1	20.6	17.0
Dividend Yield (%)	0.2	0.3	0.3	0.4	0.5	0.5	0.8
FCF per Share	94.5	57.7	87.7	58.9	-525.4	116.0	157.4
Return Ratios (%)							
RoE	19.7	20.7	24.4	27.1	14.3	10.2	13.8
RoCE	14.9	13.9	16.3	20.1	11.1	9.4	12.2
RoIC	16.4	16.0	19.1	22.6	12.5	10.0	13.3
Working Capital Ratios							
Asset Turnover (x)	0.9	0.9	1.0	1.1	0.4	0.6	0.6
Fixed Asset Turnover (x)	1.2	1.3	1.3	1.4	0.7	0.7	0.8
Debtor (Days)	68	68	64	59	55	56	61
Inventory (Days)	106	85	78	81	80	80	79
Working Capital Turnover (Days)	70	47	17	48	53	59	53
Leverage Ratio (x)							
Interest Cover Ratio	6.9	6.4	7.2	11.8	8.8	4.7	9.7
Debt/Equity	0.7	0.9	0.6	0.4	0.5	0.3	0.2

Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E	(INR m)	(INR m)
Oper. Profit/(Loss) before Tax	12,259	18,472	23,521	26,730	29,848	34,219	49,342		
Depreciation/Amorisation	6,622	7,066	8,083	7,950	11,122	22,943	22,753		
Interest/Dividends Recd.	2,479	3,187	3,421	2,320	4,499	8,010	4,371		
Direct Taxes Paid	-4,210	-3,981	-4,981	-6,030	-7,077	-8,724	-12,333		
(Inc)/Dec in WC	-3,519	-182	4,181	-2,710	-4,573	-10,504	-5,283		
CF from Operations	13,631	24,561	34,224	28,260	33,819	45,944	58,849		
Others Items	4,399	-880	-1,564	-2,410	-194	1,182	4,518		
CF from Operating incl EO Expense	18,030	23,681	32,661	25,850	33,625	47,126	63,367		
(inc)/dec in FA	-1,958	-4,152	-2,991	-5,930	-2,33,500	-3,003	-3,500		
Free Cash Flow	16,072	19,529	29,670	19,920	-1,99,875	44,123	59,867		
(Pur)/Sale of Investments	-348	474	331	350	0	0	0		
Others Items	345	-19,675	1,062	180	-674	-745	-825		
CF from Investments	-1,961	-23,354	-1,598	-5,400	-2,34,174	-3,748	-4,325		
Issue of shares	0	0	0	0	1,50,287	0	0		
Inc/(Dec) in Debt	-8,464	12,434	-13,933	-9,530	85,120	-42,000	-7,000		
Interest Paid	-2,577	-3,030	-3,710	-2,620	-4,499	-8,010	-4,371		
Dividend Paid	-6,769	-8,630	-10,153	-10,830	-8,188	-9,205	-13,362		
Others Items	0	0	0	0	5,375	-6	-5		
CF from Fin. Activity	-17,811	774	-27,796	-22,980	2,28,095	-59,222	-24,738		
Inc/Dec of Cash	-1,742	1,101	3,266	-2,530	27,546	-15,844	34,304		
Opening Balance	5,726	3,984	5,085	8,351	5,730	33,276	17,432		
Add/(less) Forex in Cash/Cash eq				-91	0	0	0		
Closing Cash and Cash Eq.	3,984	5,085	8,351	5,730	33,276	17,432	51,736		
Bank balances*	50	630	40	60	60	60	60		
Total Cash and Cash Eq.	4,034	5,715	8,391	5,790	33,336	17,492	51,796		

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	> - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

- MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendation in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement	Torrent Pharma
Analyst ownership of the stock	No

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and

interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act of Singapore .Accordingly, if a Singapore person is not, or ceases to be, such an investor, they must immediately discontinue any use of this Report and inform MOCMSPL .

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/NCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.